The expression of each subtype (NF-L, NF-M and NF-H) of neurofilament (NF) triplet proteins in the developing rat inner ear was analysed using the immunofiuorescence method (FITC). On the 15th gestational day (GD), immunostaining of NF subtypes did not occur in the otic region. On the 18th GD, positivity for NF-L and NF-M occurred in nerve fibres in both the sensory and the subepithelial layers of the inner ear but was lacking for NF-H. At 4 days after birth immunoreactivity was present for each NF subtype but with topographic differences in their distribution. The cell bodies of (different?) subpopulations of vestibular and spiral ganglion cells were immunostained with monoclonal antibodies for NF-L and NF-M, but a subpopulation of both vestibular and spiral ganglion cells showed immunoreactivity for all three NF subtypes. The vestibular nerve fibres and ganglion cells evidenced stronger positivity than cochlear nerve fibres and spiral ganglion cells. This study confirms that the cytoskeletal maturation of inner ear nerve fibres precedes the onset of at least the auditory function by several days.

Keywords:
Inner Ear, Neurofilaments NF-L, NF-M, NF-H, Rat, Development
This content is only available via PDF.
© 1995 S. Karger AG, Basel
1995
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.